Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01196390 · OUTCOME

Percentage of Participants With Pathologic Complete Response at Surgery

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer · Source last updated 2026-06-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
At the time of surgery, 5-8 weeks after completion of radiation therapy.

What was measured

Pathologic Complete Response (pCR) is evaluated after surgery and is based on the pathology review of the submitted surgical specimen. Pathologic Complete Response occurs if the pathologist determines that the resected esophageal specimen, accompanying lymph nodes, and surgical margins are all free of tumor.

Analysis population: Eligible participants who had surgery

Groups in this outcome

Chemoradiation and Trastuzumab

Radiation therapy with concurrent trastuzumab, paclitaxel, and carboplatin followed by surgery followed by maintenance trastuzumab

Chemoradiation

Radiation therapy with concurrent paclitaxel and carboplatin followed by surgery

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Chemoradiation and Trastuzumab82
Chemoradiation78

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Chemoradiation and Trastuzumab27Not reported1838Not reported
Chemoradiation29Not reported2041Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.71
    statistical Comment
    Two-sided significance level = 0.05
    statistical Method
    Chi-squared
Complete source fields
analyses
  1. group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.71
    statistical Comment
    Two-sided significance level = 0.05
    statistical Method
    Chi-squared
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        18
        upper Limit
        38
        value
        27
      2. group Id
        OG001
        lower Limit
        20
        upper Limit
        41
        value
        29
denoms
  1. counts
    1. group Id
      OG000
      value
      82
    2. group Id
      OG001
      value
      78
    units
    Participants
description
Pathologic Complete Response (pCR) is evaluated after surgery and is based on the pathology review of the submitted surgical specimen. Pathologic Complete Response occurs if the pathologist determines that the resected esophageal specimen, accompanying lymph nodes, and surgical margins are all free of tumor.
dispersion Type
95% Confidence Interval
groups
  1. description
    Radiation therapy with concurrent trastuzumab, paclitaxel, and carboplatin followed by surgery followed by maintenance trastuzumab
    id
    OG000
    title
    Chemoradiation and Trastuzumab
  2. description
    Radiation therapy with concurrent paclitaxel and carboplatin followed by surgery
    id
    OG001
    title
    Chemoradiation
param Type
NUMBER
population Description
Eligible participants who had surgery
reporting Status
POSTED
time Frame
At the time of surgery, 5-8 weeks after completion of radiation therapy.
title
Percentage of Participants With Pathologic Complete Response at Surgery
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice